Wells Fargo & Company Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock

Cardinal Health (NYSE:CAH) had its price objective upped by investment analysts at Wells Fargo & Company from $245.00 to $277.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 15.38% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the stock. Morgan Stanley raised their target price on shares of Cardinal Health from $245.00 to $255.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. UBS Group increased their price target on Cardinal Health from $260.00 to $274.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Wall Street Zen upgraded Cardinal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Citigroup increased their target price on Cardinal Health from $245.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Finally, Mizuho boosted their price target on shares of Cardinal Health from $235.00 to $240.00 and gave the company an “outperform” rating in a report on Thursday, July 23rd. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Cardinal Health has an average rating of “Moderate Buy” and an average price target of $256.73.

Cardinal Health Stock Performance

CAH opened at $240.08 on Wednesday. The company has a market capitalization of $56.23 billion, a P/E ratio of 36.71, a PEG ratio of 1.16 and a beta of 0.49. The company has a 50-day moving average of $228.37 and a 200-day moving average of $216.66. Cardinal Health has a 1-year low of $137.75 and a 1-year high of $258.30.

Cardinal Health (NYSE:CAH) last released its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.62% and a negative return on equity of 92.61%. The firm had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. During the same quarter in the previous year, the company posted $2.08 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, sell-side analysts expect that Cardinal Health will post 10.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Westpac Banking Corp acquired a new position in shares of Cardinal Health during the second quarter valued at $6,980,000. Korea Investment CORP bought a new position in Cardinal Health in the 2nd quarter valued at about $34,623,000. EP Wealth Advisors LLC acquired a new position in Cardinal Health during the 2nd quarter valued at about $1,602,000. Rakuten Securities Inc. acquired a new position in Cardinal Health during the 2nd quarter valued at about $71,000. Finally, Callan Family Office LLC bought a new stake in shares of Cardinal Health during the 2nd quarter worth about $2,700,000. Institutional investors and hedge funds own 87.17% of the company’s stock.

Trending Headlines about Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Profit and guidance beat expectations. Cardinal Health reported fiscal Q4 non-GAAP EPS of $2.91, up from $2.08 a year earlier and $0.49 above consensus. Fiscal 2027 adjusted EPS guidance of $12.40–$12.60 also exceeded the approximately $12.05 analyst estimate, implying 13%–15% growth. Cardinal Health forecasts full-year profit above estimates on specialty drug strength
• Positive Sentiment: Specialty-drug and medtech performance supported earnings. Sustained demand for specialty pharmaceuticals helped drive the outlook, while medical technology profits nearly doubled in the quarter. Cardinal also said it now exclusively serves nearly half of the cell-and-gene therapy market, strengthening its position in a higher-margin growth niche. Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
• Positive Sentiment: Large buyback authorization added support. The board approved an additional $5 billion for share repurchases after Cardinal bought back $1.4 billion of stock during fiscal 2026. The company also declared a quarterly dividend of $0.5158 per share, payable October 15. Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results
• Neutral Sentiment: Revenue growth was solid but missed forecasts. Fourth-quarter revenue rose 6% year over year to $63.67 billion, but fell short of the roughly $65.15 billion consensus estimate. Fiscal 2026 operating cash flow reached $5.2 billion and adjusted free cash flow was $5.0 billion. Cardinal Health shares rise as profit beats estimates and outlook tops forecasts
• Negative Sentiment: Some earnings quality and valuation concerns remain. About $0.31 of quarterly adjusted EPS came from a one-time IEEPA tariff refund, while the Global Medical Products and Distribution segment reported declining revenue. With CAH trading near its 52-week high and at an elevated valuation, investors may demand continued execution to justify further gains. Can Cardinal Health’s Strong Earnings Guidance Offset a Mixed Quarter?

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.